Généthon, a French clinical-stage biotech focusing on rare diseases, aims to make cell and gene therapies (CGTs) both safe and affordable by driving cost-reducing innovations in biomanufacturing. The company is developing novel methods to improve clinical efficiency and manufacturing yields, collaborating with academic and industry partners including Eukarÿs and Thales. Its goal is to reduce CGT production costs from current million-dollar per dose levels to tens of thousands, enabling broader patient access to therapies for ultra-rare conditions.